Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-106 in advanced ROS1-positive NSCLC
NCT04395677Phase 2Active, not recruiting
- Sponsor
- Nuvation Bio
- Start
- Jul 2020
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of taletrectinib in non-small cell lung cancer (NSCLC), sponsored by Nuvation Bio. Started Jul 2020; status: active, not recruiting.
02
Drugs
taletrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04395677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04395677.